Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1986 Sep;65(3):497–505.

Interleukin 2 defect in the peripheral blood and the lung in patients with Sjögren's syndrome.

N Miyasaka, N Murota, K Yamaoka, K Sato, T Yamada, T Nishido, M Okuda
PMCID: PMC1542504  PMID: 3490935

Abstract

We studied interleukin 2 (IL-2) production both in the peripheral blood and the lung in patients with Sjögren's syndrome (SS). IL-2 production of the peripheral blood mononuclear cells (PBMC) was significantly impaired in patients with SS (P less than 0.001). The patients with extraglandular disease and with associated connective tissue disease were more defective in IL-2 production. The defect could not be attributable to culture conditions. Both OKT4+ and OKT8+ T cells were deficient in producing IL-2. However, impaired IL-2 production could be partly restored by either (1) adding PMA to the PHA-stimulated culture, or (2) supplementing indomethacin (IM) from the initiation of the culture, or (3) depletion of adherent cells from PBMC. Furthermore, SS T cells were more sensitive to PGE1 than normal controls. In contrast, the response of PBMC to IL-2 was not disturbed in SS. IL-1 production of SS PBMC was not defective although there seemed to be suppressive factor(s) produced by SS adherent cells. In addition, IL-2 production of SS pulmonary lymphocytes was also decreased, suggesting that IL-2 producing cells might not be sequestrated in the lung. These data suggest that qualitative T cell defects and suppressor macrophages might be responsible for defective IL-2 production in SS and that IL-2 deficiency may contribute to the disordered immunoregulation in SS.

Full text

PDF
497

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adamson T. C., 3rd, Fox R. I., Frisman D. M., Howell F. V. Immunohistologic analysis of lymphoid infiltrates in primary Sjogren's syndrome using monoclonal antibodies. J Immunol. 1983 Jan;130(1):203–208. [PubMed] [Google Scholar]
  2. Alcocer-Varela J., Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest. 1982 Jun;69(6):1388–1392. doi: 10.1172/JCI110579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chouaib S., Fradelizi D. The mechanism of inhibition of human IL 2 production. J Immunol. 1982 Dec;129(6):2463–2468. [PubMed] [Google Scholar]
  4. Dore-Duffy P., Zurier R. B. Lymphocyte adherence in multiple sclerosis. Role of monocytes and increased sensitivity of MS lymphocytes to prostaglandin E. Clin Immunol Immunopathol. 1981 Jun;19(3):303–313. doi: 10.1016/0090-1229(81)90072-6. [DOI] [PubMed] [Google Scholar]
  5. Farrar J. J., Benjamin W. R., Hilfiker M. L., Howard M., Farrar W. L., Fuller-Farrar J. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunol Rev. 1982;63:129–166. doi: 10.1111/j.1600-065x.1982.tb00414.x. [DOI] [PubMed] [Google Scholar]
  6. Goodwin J. S., Messner R. P. Sensitivity of lymphocytes to prostaglandin E2 increases in subjects over age 70. J Clin Invest. 1979 Aug;64(2):434–439. doi: 10.1172/JCI109480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hasler F., Bluestein H. G., Zvaifler N. J., Epstein L. B. Analysis of the defects responsible for the impaired regulation of EBV-induced B cell proliferation by rheumatoid arthritis lymphocytes. II. Role of monocytes and the increased sensitivity of rheumatoid arthritis lymphocytes to prostaglandin E. J Immunol. 1983 Aug;131(2):768–772. [PubMed] [Google Scholar]
  8. Jung L. K., Hara T., Fu S. M. Detection and functional studies of p60-65 (Tac antigen) on activated human B cells. J Exp Med. 1984 Nov 1;160(5):1597–1602. doi: 10.1084/jem.160.5.1597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kilpi A., Bergroth V., Konttinen Y. T., Maury C. P., Reitamo S., Wegelius O. Lymphocyte infiltrations of the gastric mucosa in Sjögren's syndrome. An immunoperoxidase study using monoclonal antibodies in the avidin-biotin-peroxidase method. Arthritis Rheum. 1983 Oct;26(10):1196–1200. doi: 10.1002/art.1780261004. [DOI] [PubMed] [Google Scholar]
  10. Lachman L. B., Hacker M. P., Blyden G. T., Handschumacher R. E. Preparation of lymphocyte-activating factor from continuous murine macrophage cell lines. Cell Immunol. 1977 Dec;34(2):416–419. doi: 10.1016/0008-8749(77)90263-5. [DOI] [PubMed] [Google Scholar]
  11. Linker-Israeli M., Bakke A. C., Kitridou R. C., Gendler S., Gillis S., Horwitz D. A. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol. 1983 Jun;130(6):2651–2655. [PubMed] [Google Scholar]
  12. Merrill J. E., Mohlstrom C., Uittenbogaart C., Kermaniarab V., Ellison G. W., Myers L. W. Response to and production of interleukin 2 by peripheral blood and cerebrospinal fluid lymphocytes of patients with multiple sclerosis. J Immunol. 1984 Oct;133(4):1931–1937. [PubMed] [Google Scholar]
  13. Miyasaka N., Darnell B., Baron S., Talal N. Interleukin 2 enhances natural killing of normal lymphocytes. Cell Immunol. 1984 Mar;84(1):154–162. doi: 10.1016/0008-8749(84)90086-8. [DOI] [PubMed] [Google Scholar]
  14. Miyasaka N., Nakamura T., Russell I. J., Talal N. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol. 1984 Apr;31(1):109–117. doi: 10.1016/0090-1229(84)90195-8. [DOI] [PubMed] [Google Scholar]
  15. Miyasaka N., Sauvezie B., Pierce D. A., Daniels T. E., Talal N. Decreased autologous mixed lymphocyte reaction in Sjögren's syndrome. J Clin Invest. 1980 Nov;66(5):928–933. doi: 10.1172/JCI109960. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Miyasaka N., Seaman W., Bakshi A., Sauvezie B., Strand V., Pope R., Talal N. Natural killing activity in Sjögren's syndrome. An analysis of defective mechanisms. Arthritis Rheum. 1983 Aug;26(8):954–960. doi: 10.1002/art.1780260803. [DOI] [PubMed] [Google Scholar]
  17. Mizel S. B. Physicochemical characterization of lymphocyte-activating factor (LAF). J Immunol. 1979 Jun;122(6):2167–2172. [PubMed] [Google Scholar]
  18. Mizel S. B., Rosenstreich D. L. Regulation of lymphocyte-activating factor (LAF) production and secretion in P388D1 cells: identification of high molecular weight precursors of LAF. J Immunol. 1979 Jun;122(6):2173–2179. [PubMed] [Google Scholar]
  19. Murakawa Y., Takada S., Ueda Y., Suzuki N., Hoshino T., Sakane T. Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus. J Immunol. 1985 Jan;134(1):187–195. [PubMed] [Google Scholar]
  20. Prud'homme G. J., Fuks A., Colle E., Seemayer T. A., Guttmann R. D. Immune dysfunction in diabetes-prone BB rats. Interleukin 2 production and other mitogen-induced responses are suppressed by activated macrophages. J Exp Med. 1984 Feb 1;159(2):463–478. doi: 10.1084/jem.159.2.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ralph P., Jeong G., Welte K., Mertelsmann R., Rabin H., Henderson L. E., Souza L. M., Boone T. C., Robb R. J. Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2. J Immunol. 1984 Nov;133(5):2442–2445. [PubMed] [Google Scholar]
  22. Rappaport R. S., Dodge G. R. Prostaglandin E inhibits the production of human interleukin 2. J Exp Med. 1982 Mar 1;155(3):943–948. doi: 10.1084/jem.155.3.943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Strand V., Talal N. Advances in the diagnosis and concept of Sjögren's syndrome (autoimmune exocrinopathy). Bull Rheum Dis. 1979;30(9):1046–1052. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES